Anavex Life Sciences (AVXL) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChartTranscripts

AVXL Stock Forecast


Anavex Life Sciences stock forecast is as follows: an average price target of $11.00 (represents a 50.68% upside from AVXL’s last price of $7.30) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

AVXL Price Target


The average price target for Anavex Life Sciences (AVXL) is $11.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 50.68% upside from AVXL's last price of $7.30.

AVXL Analyst Ratings


Buy

According to 7 Wall Street analysts, Anavex Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for AVXL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Anavex Life Sciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 06, 2022-Cantor Fitzgerald$11.00$8.5428.85%50.68%
Row per page
Go to

The latest Anavex Life Sciences stock forecast, released on Dec 06, 2022 by Cantor Fitzgerald company, set a price target of $11.00, which represents a 28.85% increase from the stock price at the time of the forecast ($8.54), and a 50.68% increase from AVXL last price ($7.30).

Anavex Life Sciences Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.30$7.30$7.30
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Anavex Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Anavex Life Sciences's last price of $7.30. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024H.C. WainwrightBuyBuyHold
Jul 22, 2024EF Hutton-BuyInitialise
Jan 03, 2023BarclaysEqual-WeightEqual-WeightHold
Jan 03, 2023Keefe, Bruyette & WoodsOutperformOutperformHold
Jan 03, 2023NeedhamBuyBuyHold
Jan 03, 2023Piper SandlerOverweightOverweightHold
Dec 06, 2022Cantor Fitzgerald-NeutralDowngrade
Row per page
Go to

Anavex Life Sciences's last stock rating was published by H.C. Wainwright on Oct 18, 2024. The company gave AVXL a "Buy" rating, the same as its previous rate.

Anavex Life Sciences Financial Forecast


Anavex Life Sciences Revenue Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue------
Avg Forecast$111.56M$71.73M$45.53M$45.92M--
High Forecast$111.56M$71.73M$45.53M$45.92M--
Low Forecast$111.56M$71.73M$45.53M$45.92M--
# Analysts1111--
Surprise %------

Anavex Life Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVXL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Anavex Life Sciences EBITDA Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111--
EBITDA------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

undefined analysts predict AVXL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Anavex Life Sciences's previous annual EBITDA (undefined) of $NaN.

Anavex Life Sciences Net Income Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111--
Net Income------
Avg Forecast$-15.22M$-19.44M$-16.91M$-16.06M$-13.81M$-13.53M
High Forecast$-15.22M$-19.44M$-16.91M$-16.06M$-13.81M$-13.53M
Low Forecast$-15.22M$-19.44M$-16.91M$-16.06M$-13.81M$-13.53M
Surprise %------

Anavex Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVXL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Anavex Life Sciences SG&A Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111--
SG&A------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Anavex Life Sciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVXL last annual SG&A of $NaN (undefined).

Anavex Life Sciences EPS Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111--
EPS------
Avg Forecast$-0.18$-0.23$-0.20$-0.19$-0.16$-0.16
High Forecast$-0.18$-0.23$-0.20$-0.19$-0.16$-0.16
Low Forecast$-0.18$-0.23$-0.20$-0.19$-0.16$-0.16
Surprise %------

According to undefined Wall Street analysts, Anavex Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVXL previous annual EPS of $NaN (undefined).

Anavex Life Sciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BTAIBioXcel Therapeutics$0.64$12.001775.00%Buy
KODKodiak Sciences$3.90$31.60710.26%Buy
NVAXNovavax$9.12$58.00535.96%Buy
INMBINmune Bio$6.25$22.00252.00%Buy
ANVSAnnovis Bio$8.73$25.67194.04%Buy
IOVAIovance Biotherapeutics$11.44$21.0083.57%Buy
VKTXViking Therapeutics$63.14$100.5059.17%Buy
AVXLAnavex Life Sciences$7.30$11.0050.68%Buy
AXSMAxsome Therapeutics$87.25$117.8335.05%Buy
TGTXTG Therapeutics$24.36$26.408.37%Buy
MDGLMadrigal Pharmaceuticals$331.32$315.75-4.70%Buy
EXELExelixis$34.29$30.50-11.05%Buy

AVXL Forecast FAQ


Yes, according to 7 Wall Street analysts, Anavex Life Sciences (AVXL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of AVXL's total ratings.

Anavex Life Sciences (AVXL) average price target is $11 with a range of $11 to $11, implying a 50.68% from its last price of $7.3. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AVXL stock, the company can go up by 50.68% (from the last price of $7.3 to the average price target of $11), up by 50.68% based on the highest stock price target, and up by 50.68% based on the lowest stock price target.

AVXL's average twelve months analyst stock price target of $11 does not support the claim that Anavex Life Sciences can reach $11 in the near future.

Anavex Life Sciences's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-27.333M (high $-27.333M, low $-27.333M), average SG&A $0 (high $0, low $0), and average EPS is $-0.323 (high $-0.323, low $-0.323). AVXL's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $274.74M (high $274.74M, low $274.74M), average EBITDA is $0 (high $0, low $0), average net income is $-67.628M (high $-67.628M, low $-67.628M), average SG&A $0 (high $0, low $0), and average EPS is $-0.8 (high $-0.8, low $-0.8).